Article
Analysis of causes for poor persistence of CAR-T cell therapy in vivo
25 Jan 2023
Abstract excerpt
Chimeric antigen receptor T-cell (CAR-T-cell) therapy has been well researched to date because of its ability to target malignant tumor cells. The most common CAR-T cells are CD19 CAR-T cells, which play a large role in B-cell leukemia treatment. However, most CAR-T cells are associated with relapse after clinical treatment, so the quality and persistence of CAR-T cells need to be improved. With continuous...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
